Takeda announced the U.S. availability of GAMMAGARD LIQUID™ ERC, a liquid immunoglobulin therapy, for people ages two and older with primary immunodeficiency.
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC for Primary Immunodeficiency Patients
Published: January 22, 2026